ABSTRACT

Febuxostat (FEB) belongs to BCS class II, having low solubility and high permeability. Due to low solubility it is having low oral absorption that ultimately results in low oral bioavailability. Poor oral bioavailability leads to reduction in plasma drug concentration and overall reduction in therapeutic effects. The method use for the development of solid lipid nanoparticles (SLN) is high speed homogenization (HSH) with ultra-sonication; the advantage of the method is the avoidance of usage of organic solvents, as organic solvent is not most preferred because it generally leads toxicity and other problem. Optimized sonication times, rotation of HSH, speed of HSH were 2 minutes, 10,000 RPM and 10 minutes respectively. Using 32 full factorial design, drug: lipid ratio (1:18) and surfactant concentration (0.7%) were optimized. Optimized batch of FEB SLN had mean particle size 193.4±4.23 nm, Polydispersibility index 82.93 ±1.6 % and surface charge -21.5 mv. From FTIR, and DSC studies of FEB, Lipids and optimized formulation it can be conclude that FEB was properly loaded in SLN. From TEM results, we can conclude that prepared SLN had Spherical shape & smooth surface. From in- vitro and Ex -vivo drug release profile, it can be concluded that FEB SLN gave sustained release as 100% CDR obtained after 24 hours. Key words: High speed homogenization with ultra-sonication, SLN, Ex vivo, TEM, Full factorial design
Publication date: 01/10/2021

https://ijbpas.com/pdf/2021/October/MS_IJBPAS_2021_OCT_SPCL_1018.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.10.1018